The evolving treatment landscape of hepatocellular carcinoma: more choices, more responsibility.
作者信息
Gill S
机构信息
BC Cancer and University of British Columbia, Vancouver, BC.
出版信息
Curr Oncol. 2020 Nov;27(Suppl 3):S136-S137. doi: 10.3747/co.27.6143. Epub 2020 Nov 1.
Abstract
摘要
相似文献
1
The evolving treatment landscape of hepatocellular carcinoma: more choices, more responsibility.肝细胞癌不断变化的治疗格局：选择更多，责任更大。
Curr Oncol. 2020 Nov;27(Suppl 3):S136-S137. doi: 10.3747/co.27.6143. Epub 2020 Nov 1.
2
Advances in liver fibrosis imaging and hepatocellular carcinoma: update in 2013. Preface.肝纤维化成像与肝细胞癌的进展：2013年最新情况。前言。
Oncology. 2013;84 Suppl 1:1-2. doi: 10.1159/000345882. Epub 2013 Feb 20.
3
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers.肝细胞癌全身治疗的发展态势：突破、毒性及未来前沿
Am Soc Clin Oncol Educ Book. 2019 Jan;39:248-260. doi: 10.1200/EDBK_237555. Epub 2019 May 17.
4
Biomarkers for hepatocellular carcinoma.肝细胞癌的生物标志物。
Clin Adv Hematol Oncol. 2016 Apr;14(4):223-34.
5
Challenges of Clinical Research on Hepatocellular Carcinoma.肝细胞癌临床研究的挑战
Dig Dis. 2015 Oct;33(6):780-90. doi: 10.1159/000439103. Epub 2015 Oct 21.
6
The evolving role of radioembolization in hepatocellular carcinoma.放射性栓塞在肝细胞癌中不断演变的作用。
Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):14-17.
7
A translational worldwide perspective for liver cancer - First International Meeting.肝癌的全球转化视角——首届国际会议
IDrugs. 2007 Sep;10(9):630-2.
8
The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy.肝细胞癌不断变化的格局：病因、遗传学与治疗
Am J Pathol. 2014 Mar;184(3):574-83. doi: 10.1016/j.ajpath.2013.10.028. Epub 2013 Dec 31.
9
Endobronchial metastasis from hepatocellular carcinoma - a case description with literature review.肝细胞癌的支气管内转移——病例描述及文献综述
Int J Clin Exp Pathol. 2013 Aug 15;6(9):1942-7. eCollection 2013.
10
Rethinking Resection and Transplant Candidacy for HCC: Should Tumor Biology Replace Size-Based Criteria?重新思考肝癌的切除与移植候选资格：肿瘤生物学是否应取代基于大小的标准？
Ann Surg Oncol. 2020 May;27(5):1309-1311. doi: 10.1245/s10434-019-08081-5. Epub 2019 Nov 14.
引用本文的文献
1
Prognostic Significance of CCDC137 Expression and Its Association with Immune Infiltration in Hepatocellular Carcinoma.CCDC137 表达的预后意义及其与肝癌免疫浸润的关系。
Dis Markers. 2022 Aug 24;2022:5638675. doi: 10.1155/2022/5638675. eCollection 2022.
本文引用的文献
1
Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.一线系统治疗后肝癌进展的管理：二线及以上治疗中最佳序贯策略的定义。
Curr Oncol. 2020 Nov;27(Suppl 3):S173-S180. doi: 10.3747/co.27.7103. Epub 2020 Nov 1.
2
Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.索拉非尼和仑伐替尼在晚期疾病中的作用不断演变：探索肝细胞癌一线治疗的非免疫治疗选择。
Curr Oncol. 2020 Nov;27(Suppl 3):S165-S172. doi: 10.3747/co.27.7159. Epub 2020 Nov 1.
3
Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.免疫疗法在肝细胞癌治疗中的作用：当前标准和未来方向。
Curr Oncol. 2020 Nov;27(Suppl 3):S152-S164. doi: 10.3747/co.27.7315. Epub 2020 Nov 1.
4
Current locoregional therapies and treatment strategies in hepatocellular carcinoma.当前肝癌的局部区域治疗和治疗策略。
Curr Oncol. 2020 Nov;27(Suppl 3):S144-S151. doi: 10.3747/co.27.7171. Epub 2020 Nov 1.
5
Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.肝细胞癌：流行病学、筛查和肝储备功能评估。
Curr Oncol. 2020 Nov;27(Suppl 3):S138-S143. doi: 10.3747/co.27.7181. Epub 2020 Nov 1.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件